S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
Why Your IRA Could Crash on January 16th? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
Why Your IRA Could Crash on January 16th? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
Why Your IRA Could Crash on January 16th? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Thousands protest in South Korea in support of truckers
Why Your IRA Could Crash on January 16th? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
NASDAQ:ORMP

Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

$8.65
+0.31 (+3.72%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.14
$8.77
50-Day Range
$5.88
$9.00
52-Week Range
$3.59
$17.64
Volume
251,729 shs
Average Volume
311,185 shs
Market Capitalization
$338.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
235.3% Upside
$29.00 Price Target
Short Interest
Bearish
7.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.91) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

926th out of 1,034 stocks

Pharmaceutical Preparations Industry

449th out of 502 stocks

ORMP stock logo

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

ORMP: Data from NASH Phase 2 Study – Positive Takeaways
Oramed Reports Third Quarter 2022 Financial Results
ORMP Oramed Pharmaceuticals Inc.
Oramed Oral Insulin Shows Evidence For NASH Treatment
Oramed Pharmaceuticals Inc. (ORMP)
Short Volatility Alert: Oramed Pharmaceuticals Inc.
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings
1/10/2022
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
1/10/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+235.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-22,240,000.00
Net Margins
-550.52%
Pretax Margin
-1,373.37%

Debt

Sales & Book Value

Annual Sales
$2.70 million
Book Value
$3.92 per share

Miscellaneous

Free Float
36,416,000
Market Cap
$338.39 million
Optionable
Optionable
Beta
2.32

Key Executives

  • Mr. Nadav  Kidron Esq.Mr. Nadav Kidron Esq. (Age 48)
    Pres, CEO & Exec. Chairman
    Comp: $1.23M
  • Mr. David Silberman CPA (Age 38)
    CFO & Treasurer
    Comp: $232.47k
  • Mr. Joshua Hexter (Age 52)
    Chief Operating & Bus. Officer
    Comp: $326.94k
  • Dr. Miriam Kidron Ph.D. (Age 82)
    Chief Scientific Officer & Director
    Comp: $420.06k
  • Mr. Michael Rabinowitz (Age 57)
    Chief Commercial Officer
    Comp: $360.18k
  • Mr. Netanel Derovan (Age 47)
    Chief Legal Officer & Company Sec.
  • Dr. Roy Eldor M.D.
    Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board













ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORMP shares.
View ORMP analyst ratings
or view top-rated stocks.

What is Oramed Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 12 month price targets for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $20.00 to $35.00. On average, they predict the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 235.3% from the stock's current price.
View analysts price targets for ORMP
or view top-rated stocks among Wall Street analysts.

How have ORMP shares performed in 2022?

Oramed Pharmaceuticals' stock was trading at $14.28 on January 1st, 2022. Since then, ORMP shares have decreased by 39.4% and is now trading at $8.65.
View the best growth stocks for 2022 here
.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 10th 2023.
View our ORMP earnings forecast
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 550.52% and a negative trailing twelve-month return on equity of 9.29%.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Jess S & Co. Inc. (0.94%), Two Sigma Advisers LP (0.85%), Two Sigma Investments LP (0.42%), Cubist Systematic Strategies LLC (0.30%), BlackRock Inc. (0.26%) and ETF Managers Group LLC (0.24%). Insiders that own company stock include Kevin Rakin and Nadav Kidron.
View institutional ownership trends
.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $8.65.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $338.39 million and generates $2.70 million in revenue each year. The biotechnology company earns $-22,240,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 12/4/2022 by MarketBeat.com Staff